News | December 31, 2014

Transcatheter Technologies Expands Platform with Transfemoral System

Product will complement Trinity TAVI

Heart valve repair, Trinity Transapical TAVI system

Image courtesy of Transcatheter Technologies GmBH

December 31, 2014 — Transcatheter Technologies GmbH announced that it has expanded the Trinity technology platform to include a transfemoral version.

In September 2014, Transcatheter Technologies disclosed the one year follow up results of its Trinity transapical TAVI system. Unlike currently marketed TAVI systems, the Trinity aortic valve can be positioned or even repositioned after a full implantation in a safe manner. Trinity’s sealing cuff provides results without PVL, a well-known and frequent complication of TAVI. The risk of atrio-ventricular (AV) block has been essentially alleviated because of the supra-annular anchoring of the Trinity valve.

For more information: www.transcatheter-technologies.com/home.html

Related Content

Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology | December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology | November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology | November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology | November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Videos | Heart Valve Technology | November 08, 2017
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the
Overlay Init